APA (7th ed.) Citation

Meng, X., Yang, X., Hong, Y., Wang, W., Zhang, Z., Xia, J., . . . Wang, F. (2025). Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: An exploratory multicenter, single-arm phase II clinical trial. Molecular cancer, 24(1), 175-13. https://doi.org/10.1186/s12943-025-02376-w

Chicago Style (17th ed.) Citation

Meng, Xiangrui, et al. "Anlotinib Combined with Benmelstobart as a Chemo-free First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma: An Exploratory Multicenter, Single-arm Phase II Clinical Trial." Molecular Cancer 24, no. 1 (2025): 175-13. https://doi.org/10.1186/s12943-025-02376-w.

MLA (9th ed.) Citation

Meng, Xiangrui, et al. "Anlotinib Combined with Benmelstobart as a Chemo-free First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma: An Exploratory Multicenter, Single-arm Phase II Clinical Trial." Molecular Cancer, vol. 24, no. 1, 2025, pp. 175-13, https://doi.org/10.1186/s12943-025-02376-w.